Development of acute myeloid leukemia after chemotherapy for osteosarcoma

Clinical Orthopaedics and Related Research

Volumn 391, Issue , 2001, Pages 239-246

  Kawai, Akira ^a   Sugihara, Shinsuke ^a   Naito, Noriko ^a   Ozaki, Toshifumi ^a   Isu, Kazuo ^b   Hatae, Yoshio ^b   Inoue, Hajime ^a  

^a OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DOXORUBICIN; GYRASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CASE REPORT; DRUG EFFECT; FEMALE; HUMAN; LEUKEMOGENESIS; MALE; OSTEOSARCOMA; PRIORITY JOURNAL;

EID: 0034792623     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-200110000-00027     Document Type: Article

References (48)

1. Neoadjuvant chemotherapy for extremity osteosarcoma: Preliminary results of the Rizzoli's 4th study
2. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
3. Improved prognosis of acute nonlymphocytic leukemia in children: Results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group
4. Incidence of second cancers in patients treated for Hodgkin's disease
5. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma
6. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites
7. Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer
8. Secondary leukemia with a translocation (8;21)?
9. A system of staging musculoskeletal neoplasms
10. The p53 gene in pediatric therapy-related leukemia and myelodysplasia
11. Association of CYP3A4 genotype with treatment-related leukemia
12. Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: Good response to antileukemic drugs
13. Ifosfamide and etoposide in childhood osteosarcoma: A phase II study of the French society of paediatric oncology
14. Survival, prognosis, and therapeutic response in osteogenic sarcoma: The Memorial Hospital experience
15. Second malignant tumors following treatment during childhood and adolescence for cancer
16. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study 3: An interim report
17. Osteosarcoma Study Group: The result of a cooperative study of chemotherapy for osteosarcoma (NECO 93J)
18. Prognostic results from multi-institute study of adjuvant chemotherapy for osteogenic sarcoma
19. Acute myelogenous leukemia following radiation therapy and chemotherapy for osteogenic sarcoma
20. Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloroplatinum-II-based regimen for osteosarcoma
21. Therapy-related leukemia and myelodysplastic syndrome
22. Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features
23. The association of specific 'favorable' cytogenetic abnormalities with secondary leukemia
24. Acute lymphoblastic leukemia with t(4;11) translocation after osteogenic sarcoma
25. The molecular pathogenesis of treatment-induced (secondary) leukemias: Foundations for treatment and prevention
26. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors
27. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol
28. Ifosfamide/etoposide alternating with high-dose methotrexate: Evaluation of a chemotherapy regimen for poor-risk osteosarcoma
29. Incidence of second malignant neoplasms in children: Results of an international study
30. A case of secondary leukemia complicating therapy for osteosarcoma
31. Acute lymphoblastic leukemia in a girl treated for osteosarcoma
32. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia
33. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP 53 mutations
34. Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma
35. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
36. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer
37. Second malignant neoplasms occurring in survivors of osteosarcoma
38. Myeloid neoplasia in children treated for solid tumours
39. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature
40. Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung
41. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
42. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation
43. Therapy-related leukemia associated with high-dose 4-epidoxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer
44. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks
45. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup
46. Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL)
47. Japan Adult Leukemia Study Group (JALSG)-Twelve years of activities and future direction
48. Cytogenetic studies in patients with secondary leukemia/ dysmyelopoietic syndrome after different treatment modalities